Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Harrison, CN; Gupta, VK; Gerds, AT; Rampal, R; Verstovsek, S; Talpaz, M; Kiladjian, JJ; Mesa, R; Kuykendall, AT; Vannucchi, AM; Palandri, F; Grosicki, S; Devos, T; Jourdan, E; Wondergem, MJ; Al-Ali, HK; Buxhofer-Ausch, V; Alvarez-Larran, A; Patriarca, A; Kremyanskaya, M; Mead, AJ; Akhani, S; Sheikine, Y; Colak, G; Mascarenhas, J

Mascarenhas, J (通讯作者)，Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Oncol, New York, NY 10029 USA.

FUTURE ONCOLOGY, 2022; 18 (27): 2987

Abstract

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索